What is the primary role of beta blockers in patients with HFpEF and atrial fibrillation?

In patients with heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation, beta blockers play a crucial role mainly in providing rate control. Atrial fibrillation often leads to a rapid and irregular heart rate, which can exacerbate symptoms of heart failure and worsen overall cardiac function. By administering beta blockers, the heart rate can be effectively managed, allowing for improved diastolic filling of the ventricles, better coronary perfusion, and an overall alleviation of symptoms related to heart failure.

Controlling the heart rate is vital because it helps stabilize the rhythm, contributing to patient comfort and reducing the risk of complications associated with elevated heart rates. This is particularly important in HFpEF, where maintaining an adequate heart rate is essential for optimal cardiac performance despite the preserved ejection fraction.

The other choices do not accurately reflect the primary action of beta blockers in this context. While they may have some effects on blood pressure or arrhythmias, their most significant benefit in this scenario revolves around controlling the heart rate.